Brief: Vir Biotechnology Inc's Executive Vice President And Chief Operating Officer, Johanna Friedl-Naderer, Will Be Leaving Co On Sept 29
20/09/2023 12:15
Sept 20 (Reuters) - Vir Biotechnology Inc VIR.O :
* VIR BIOTECHNOLOGY INC: JOHANNA FRIEDL-NADERER, COMPANY'S
EXECUTIVE VICE PRESIDENT AND CHIEF OPERATING OFFICER, WILL BE
LEAVING CO ON SEPT 29
Source text: [ID:https://l1nq.com/1QJjD]
Further company coverage: VIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO